BRENT KINSEY: Open Payments
NPI 1528136868 · IOWA CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$891 in 42 payments from 17 companies in 2025. Trend: 2023 $710 · 2024 $1,620 · 2025 $891
Food & beverage: $891
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $211 |
| AstraZeneca Pharmaceuticals LP | 5 | $186 |
| ABBVIE INC. | 4 | $95 |
| Lilly USA, LLC | 4 | $58 |
| Abbott Laboratories | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Dexcom, Inc. | 2 | $35 |
| Boston Scientific Corporation | 1 | $35 |
| Astellas Pharma US Inc | 1 | $35 |
| Seqirus USA Inc | 1 | $31 |
Products named: Wegovy, BREZTRI, AIRSUPRA, QULIPTA, FREESTYLE LIBRE 3, Ozempic, CAPLYTA, Dexcom G6 Transmitter.
Industry payments across IA — which companies pay providers there.
